Lung and head and neck cancer (HNC) are the leading cause of cancer death and the most psychologically distressing cancer, respectively;both are largely tobacco induced. The overall goal of the Lung, Head and Neck (LHN) Program is to translate fundamental scientific research discoveries into preventive and therapeutic interventions and thereby decrease the incidence and mortality of lung and HNC. These goals are achieved by fostering collaborations between scientists focused on population, behavioral, basic, clinical, therapeutic and translational studies. The LHN Program has 3 focus groups: 1) Risk Biomarkers, Early Detection and Prevention. 2) Tumor Genetics and Biology. 3) Experimental Therapeutics. In one strategy to accomplish our goal, our members are developing genetically engineered mouse models to characterize LHN-specific genetic aberrations and test novel chemopreventive strategies and targeted therapies in a setting of naturally occurring spontaneous cancer. These are complemented by direct patient tumor xenograft models to test personalized targeted therapies. Tumors developed from these models together with primary patient samples are subjected to high throughput genetic/epigenetic/protein analyses for discovery of prognostic and predictive biomarkers. Research using these cutting-edge models has and will continue to translate into investigator-initiated clinical trials that incorporate clinical biomarkers. In the previous funding period the program made several major contributions to the field including: 1. The first Phase II chemoprevention trial to demonstrate improvement in endobronchial dysplasia (Iloprost trial);2.Development of biomarkers to predict sensitivity to EGFR and ALK TKIs;3. Development of genetically engineered mouse models for HNC;4. Development and validation of biomarkers of lung cancer risk and diagnosis, and;5. Fundamental research leading to a trial of EGFR and HDAC inhibition. LHN consists of 31 Full members from 11 departments in 6 schools at 4 consortium institutions. Members currently hold $5.2M in NCI grant support and $11.5M in other cancer relevant research support. Per capita cancer research funding has increased by 88% from $287K in 2005 to $539K in 2010. Over the same period, LHN members produced 380 cancer-related publications of which 101 (27%) were interprogrammatic; 38 (10%) were intra-programmatic and 101 (27%) were both inter- and intra-programmatic for a total of 240 (63%) collaborative publications.

Public Health Relevance

Lung and head and neck cancer are the leading cause of cancer death and the most psychologically distressing cancer, respectively. Both are largely tobacco induced, affect the respiratory tract and share many biologic features. The LHN Program moves basic science findings to clinical practice, exemplified by the discovery of predictive biomarkers to guide therapeutic strategies, early detection and prevention advances and the use of genetic models of cancer to understand the biology of these malignancies.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046934-26
Application #
8616642
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
26
Fiscal Year
2014
Total Cost
$25,698
Indirect Cost
$10,404
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Gillen, Austin E; Yamamoto, Tomomi M; Kline, Enos et al. (2016) Improvements to the HITS-CLIP protocol eliminate widespread mispriming artifacts. BMC Genomics 17:338
Saichaemchan, S; Ariyawutyakorn, W; Varella-Garcia, M (2016) Fibroblast Growth Factor Receptors: From the Oncogenic Pathway to Targeted Therapy. Curr Mol Med 16:40-62
Eckwahl, Matthew J; Arnion, Helene; Kharytonchyk, Siarhei et al. (2016) Analysis of the human immunodeficiency virus-1 RNA packageome. RNA 22:1228-38
Justice, Cristina M; Bishop, Kevin; Carrington, Blake et al. (2016) Evaluation of IRX Genes and Conserved Noncoding Elements in a Region on 5p13.3 Linked to Families with Familial Idiopathic Scoliosis and Kyphosis. G3 (Bethesda) 6:1707-12
Seedorf, Gregory; Metoxen, Alexander J; Rock, Robert et al. (2016) Hepatocyte growth factor as a downstream mediator of vascular endothelial growth factor-dependent preservation of growth in the developing lung. Am J Physiol Lung Cell Mol Physiol 310:L1098-110
Iguchi, Nao; Malykhina, Anna P; Wilcox, Duncan T (2016) Inhibition of HIF Reduces Bladder Hypertrophy and Improves Bladder Function in Murine Model of Partial Bladder Outlet Obstruction. J Urol 195:1250-6
Helfrich, Barbara A; Kim, Jihye; Gao, Dexiang et al. (2016) Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther 15:2314-2322
Agarwal, Neeraj; Dancik, Garrett M; Goodspeed, Andrew et al. (2016) GON4L Drives Cancer Growth through a YY1-Androgen Receptor-CD24 Axis. Cancer Res 76:5175-85
Scott, Aaron J; Lieu, Christopher H; Messersmith, Wells A (2016) Therapeutic Approaches to RAS Mutation. Cancer J 22:165-74
Munson, Daniel J; Egelston, Colt A; Chiotti, Kami E et al. (2016) Identification of shared TCR sequences from T cells in human breast cancer using emulsion RT-PCR. Proc Natl Acad Sci U S A 113:8272-7

Showing the most recent 10 out of 1302 publications